SDC1 and plasma cell myeloma: Although it was toxic to CD138-selected bone marrow cells from the same patients, barasertib was reported to suppress tumor growth and induce cell death with an acceptable safety profile in a murine myeloma xenograft model (Evans R. P. et al., 2008).